Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pathogenesis(pgns) -- Ignore unavailable to you. Want to Upgrade?

To: Mel Spivak who wrote (115)	11/22/1998 1:33:00 PM
From: DJ	Read Replies (2) \| Respond to of 228

The Wall Street Journal had a front-page article last Thursday, Nov 19, profiling the CEO of a small Colorado hospital who suffers from cystic fibrosis and who has benefited enormously from Pathogenesis' new drug, Tobi. While the thesis of the article was the hospital CEO's conflict between the need to control drug costs and the fact that this (expensive) new drug is lengthening his life, the fact that companies such as PGNS are successfully developing drugs for chronic lung diseases isn't being lost on some investors.